Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1078233

Cover Image

PUBLISHER: DataM Intelligence | PRODUCT CODE: 1078233

Global Klinefelter Syndrome Treatment Market - 2022-2029

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4350
PDF & Excel (Multiple User License)
USD 4850
PDF & Excel (Enterprise License)
USD 7850

Add to Cart

Market Overview

The global klinefelter syndrome treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

When a boy is born with an extra copy of the X chromosome, he is diagnosed with Klinefelter syndrome. Klinefelter syndrome is a male-specific genetic disorder that is frequently diagnosed in adulthood.

Market Dynamics

The factors influencing the global klinefelter syndrome treatment market are the increasing research and development for the treatment and the growing prevalence of klinefelter syndrome.

The increasing research and development for the treatment of klinefelter syndrome is expected to drive the market growth

KS can affect many aspects of a person's life, beginning as early as conception. As a result, many NICHD branches, sections, and laboratories conduct research on males with XXY or poly-KS variations. Because an unusual number of sex chromosomes causes KS, research into these chromosomes is critical for finding ways to prevent or cure KS. Several divisions of the Division of Intramural Research are looking into these issues. According to the epigenetics and development section, the X chromosome genes influence the brain, reproductive, metabolic, and immune system development. The Section on Gamete Development studies the fruit fly to learn more about early gamete cell division and how an extra X chromosome can be included. Other researchers are looking into how male germ cells form before and after fertilization and how they can contain an extra X. In the Clinical Genomics Section, researchers apply what they've learned from biochemical and genomic studies to clinical investigations, as well as looking into the biomechanical mechanisms that may play a role in genetic disorders.

Infertility is a common symptom of KS, and many NICHD researchers are working to improve our understanding of how sperm production fails early in development. Scientists in the Clinical Genomics Section created mouse models to study proteins that may be important in sperm production. Aside from infertility, researchers are looking for ways to treat other KS symptoms. The Child Development and Behavior Branch (CDBB) investigates the behavioral, neurobiological, and genetic aspects of normal development, focusing on factors that may jeopardize normal development. Researchers at the CDBB are also looking into ways to prevent problems in the first place and the best conditions and timing for intervention when needed.

Limitations associated with the treatment of klinefelter syndrome are expected to hamper the market growth

Not all males with XXY condition benefit from testosterone therapy. For instance, the benefits of taking testosterone for men whose testosterone levels are low to normal are less clear than those whose testosterone levels are extremely low. Acne, skin rashes from patches or gels, breathing issues (especially while sleeping), and an increased risk of an enlarged prostate gland or prostate cancer as you get older are all possible side effects. Supplementing with testosterone does not affect testicular size, breast growth, or infertility. Although most boys with KS grow up to be males, some develop gender identities that are not typical of their gender. Supplemental testosterone may not be appropriate for these men. Before beginning treatment, it's important to talk to the doctor about gender identity.

COVID-19 Impact Analysis

SARS-Cov-2 infection was found to be common in 10% of KS patients. The presence of an extra X chromosome in all infected patients resulted in mild symptoms, supporting the theory that the presence of an extra X chromosome influences a better clinical outcome. The development of infection was not protected by testicular atrophy. SARS-CoV-2 infection was significantly associated with the presence of one affected cohabitant. The link between SARS-CoV-2 and hypogonadism was confirmed, but the formulation of the TRT (Testosterone Replacement Therapy) was unimportant. Hence, covid-19 is expected to impact the market growth positively.

Segment Analysis

Testosterone Replacement Therapy is expected to dominate the market growth

Testosterone replacement therapy can be started at the onset of puberty to help stimulate changes that occur naturally during puberty, such as developing a deeper voice, growing facial and body hair, and increasing muscle mass and sexual desire (libido). Testosterone replacement therapy can also help with bone density, fracture prevention, and mood and behavior. Historically, testosterone replacement therapy was initiated around the age of 12 years. The dose gradually increased until sufficient to maintain age-appropriate testosterone, estradiol, follicle-stimulating hormone (FSH), and luteinizing hormone serum concentrations (LH). The Association for X and Y Chromosome Variations (AXYS) advocates carefully monitoring puberty development and progression to determine when testosterone treatment should be started. Some XXY males may request gender counseling. Testosterone replacement therapy corrects androgen deficiency, promoting body proportion normalization and the development of normal male secondary sex characteristics. Low testosterone and infertility are the main symptoms of Klinefelter's Syndrome (KS). Testosterone replacement therapy (TRT) is usually prescribed when testosterone levels fall below normal. TRT can have many positive effects, but the magnitude of those effects varies from person to person. For instance, increased self-assurance, increased self-confidence, thought processes clarification, possible reduction in the risk of osteoporosis, growing facial and body hair, increased muscle mass, and increased endurance.

Geographical Analysis

North America region is expected to hold the largest market share in the global klinefelter syndrome treatment market

The growing prevalence of klinefelter syndrome and better healthcare facilities in this region are expected to drive the market growth.

The most common human sex chromosome disorder is Klinefelter syndrome (XXY aneuploidy). An extra X chromosome is present in every 500-600 males. Mentally challenged males have a 5-20 times higher prevalence rate than the general male population. Klinefelter syndrome affects about 250,000 men in the United States.

Moreover, on 27th March 2019, Jatenzo (testosterone undecanoate), an oral testosterone capsule, was approved by the US Food and Drug Administration to treat men with certain types of hypogonadism. Due to medical conditions such as genetic disorders like Klinefelter syndrome or pituitary tumors, these men have low testosterone levels.

Competitive Landscape

The global klinefelter syndrome treatment market is moderately competitive with mergers, acquisitions and product launches. Some of the key players in the market are Allergan, AbbVie, Inc., Endo Pharmaceuticals, Inc., Kyowa Kirin International plc, Eli Lilly and Company, Mylan N.V., Lupin Pharmaceuticals, Pfizer, Inc., The Simple Pharma Company UK Limited., Novartis AG

Endo Pharmaceuticals, Inc.

Overview: Endo International plc, based in Dublin, Ireland, is a generics and specialty branded pharmaceutical company. The company was founded in 1997. The specialty portfolio of Endo Pharmaceuticals includes products for urology, men's health, orthopaedics, and endocrinology.

Product Portfolio: TESTIM is an androgen used for testosterone replacement therapy in men who have a deficiency or absence of endogenous testosterone congenital or acquired primary hypogonadism, hypogonadotropic hypogonadism.

Why Purchase the Report?

Visualize the composition of the global klinefelter syndrome treatment market segmentation by treatment type and end user highlighting the key commercial assets and players.

Identify commercial opportunities in global klinefelter syndrome treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global klinefelter syndrome treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global klinefelter syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Product Code: DMOT5155

Table of Contents

1. Klinefelter Syndrome Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Klinefelter Syndrome Treatment Market- Market Definition and Overview

3. Klinefelter Syndrome Treatment Market- Executive Summary

  • 3.1. Market Snippet By Treatment Type
  • 3.2. Market Snippet By End User
  • 3.3. Market Snippet By Region

4. Klinefelter Syndrome Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The increasing research and development for the treatment of klinefelter syndrome
    • 4.1.2. Restraints:
      • 4.1.2.1. Limitations associated with the treatment of klinefelter syndrome
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Klinefelter Syndrome Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs

6. Klinefelter Syndrome Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Klinefelter Syndrome Treatment Market-By Treatment Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.3. Market Attractiveness Index, By Treatment Type
    • 7.3.1. Testosterone Replacement Therapy*
      • 7.3.1.1.1. Introduction
      • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.3.2. Fertility Treatment
    • 7.3.3. Surgeries
    • 7.3.4. Hormone Treatment
    • 7.3.5. Others

8. Klinefelter Syndrome Treatment Market- By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Academic & Research Centers
  • 8.5. Other

9. Klinefelter Syndrome Treatment Market- By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Klinefelter Syndrome Treatment Market- Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Klinefelter Syndrome Treatment Market- Company Profiles

  • 11.1. Endo Pharmaceuticals, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Allergan
  • 11.3. AbbVie, Inc.
  • 11.4. Kyowa Kirin International plc
  • 11.5. Eli Lilly and Company
  • 11.6. Lupin Pharmaceuticals
  • 11.7. Pfizer, Inc.
  • 11.8. Mylan N.V.
  • 11.9. The Simple Pharma Company UK Limited.
  • 11.10. Novartis AG

LIST NOT EXHAUSTIVE

12. Klinefelter Syndrome Treatment Market- DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!